Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska

• Published in: Vaccine 2015-09, Vol.33 (38), p.4813-4819
• Main Authors: Bruce, Michael G, Singleton, Rosalyn, Bulkow, Lisa, Rudolph, Karen, Zulz, Tammy, Gounder, Prabhu, Hurlburt, Debby, Bruden, Dana, Hennessy, Thomas
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Alaska; Alaska - epidemiology; Allergy and Immunology; Carriage; Carrier State - epidemiology; Carrier State - microbiology; Carrier State - prevention & control; Child; Child, Preschool; Disease control; Female; Humans; Immunization; Infant; Infant, Newborn; Invasive pneumococcal disease; Male; Middle Aged; Pneumococcal Infections - epidemiology; Pneumococcal Infections - microbiology; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines - administration & dosage; Pneumococcal Vaccines - immunology; Pneumonia; Serogroup; Serotype; Streptococcus pneumoniae; Streptococcus pneumoniae - classification; Streptococcus pneumoniae - isolation & purification; Vaccine; Vaccines; Young Adult
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2015.07.080

Abstract Background Alaska Native (AN) children have experienced high rates of invasive pneumococcal disease (IPD). In March 2010, PCV13 was introduced statewide in Alaska. We evaluated the impact of PCV13 on IPD in children and adults, 45 months after introduction. Methods Pneumococcal sterile site isolates, reported through state-wide surveillance, were serotyped using standard methods. We defined a pre-PCV13 time period 2005–2008 and post-PCV13 time period April 2010–December 2013; excluding Jan 2009–March 2010 because PCV13 was introduced pre-licensure in one high-risk region in 2009. Results Among Alaska children